| Recruiting | Testing the Effectiveness of the Anti-cancer Drug, Mirdametinib, in Treating Relapsed, Refractory Chronic Lymp NCT07061951 | National Cancer Institute (NCI) | Phase 2 |
| Recruiting | Anti-CD19/20/22 Chimeric Antigen Receptor T Cells (TriCAR19.20.22 T Cells) for the Treatment of Relapsed or Re NCT07166419 | Ohio State University Comprehensive Cancer Center | Phase 1 |
| Recruiting | Q702 for the Treatment of Patients With Hematologic Malignancies NCT06712810 | Mayo Clinic | Phase 1 |
| Recruiting | Sonrotoclax, Rituximab, and Zanubrutinib in Treating Participants With Chronic Lymphocytic Leukemia, Small Lym NCT06839053 | Fred Hutchinson Cancer Center | Phase 2 |
| Terminated | Genetically Engineered Cells (EGFRt/19-28z/IL-12 CAR T Cells) for the Treatment of Relapsed or Refractory CD19 NCT06343376 | Roswell Park Cancer Institute | Phase 1 |
| Recruiting | B-Cell Activating Factor Receptor (BAFFR)-Based Chimeric Antigen Receptor T-Cells With Fludarabine and Cycloph NCT06191887 | Mayo Clinic | Phase 1 |
| Active Not Recruiting | A Study of BGB-21447, a Bcl-2 Inhibitor, in Mature B-Cell Malignancies NCT05828589 | BeOne Medicines | Phase 1 |
| Recruiting | Acalabrutinib in Combination With Venetoclax for the Treatment of Refractory or Recurrent Chronic Lymphocytic NCT04941716 | Fred Hutchinson Cancer Center | Phase 2 |
| Recruiting | CD19-Directed CAR-T Cell Therapy for the Treatment of Relapsed/Refractory B Cell Malignancies NCT04892277 | Mayo Clinic | Phase 1 |
| Withdrawn | Ipilimumab, Ibrutinib, and Nivolumab for the Treatment of Chronic Lymphocytic Leukemia and Richter Transformat NCT04781855 | M.D. Anderson Cancer Center | Phase 1 |
| Recruiting | Genetically Engineered Cells (Anti-CD19/CD20/CD22 CAR T-cells) for the Treatment of Relapsed or Refractory Lym NCT05418088 | Sumithira Vasu | Phase 1 |
| Recruiting | Venetoclax Resistance Landscape in Chronic Lymphocytic Leukemia NCT05246345 | University Hospital, Clermont-Ferrand | — |
| Terminated | A Study to Evaluate VIP152 in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia or Richter Syndro NCT04978779 | Vincerx Pharma, Inc. | Phase 1 |
| Recruiting | Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hemat NCT04195633 | Fred Hutchinson Cancer Center | Phase 2 |
| Active Not Recruiting | Acalabrutinib, Umbralisib, and Ublituximab (AU2) In Relapsed and Untreated CLL NCT04624633 | Jennifer R. Brown, MD, PhD | Phase 2 |
| Terminated | Daratumumab and Ibrutinib for the Treatment of Relapsed or Refractory Chronic Lymphocytic Leukemia, DIRECT Stu NCT04230304 | Mayo Clinic | Phase 2 |
| Completed | CC-486, Lenalidomide, and Obinutuzumab for the Treatment of Recurrent or Refractory CD20 Positive B-cell Lymph NCT04578600 | Joseph Tuscano | Phase 1 |
| Withdrawn | Rituximab, Idelalisib, and Venetoclax in Relapsed/Refractory CLL/SLL NCT03639324 | Virginia Commonwealth University | Phase 1 |
| Recruiting | Acalabrutinib and Venetoclax With or Without Early Obinutuzumab for the Treatment of High Risk, Recurrent, or NCT04169737 | M.D. Anderson Cancer Center | Phase 2 |
| Terminated | CD19-Specific T Cells Post AlloSCT NCT03579888 | M.D. Anderson Cancer Center | Phase 1 |
| Active Not Recruiting | Nivolumab for Relapsed, Refractory, or Detectable Disease Post Chimeric Antigen Receptor T-cell Treatment in P NCT04205409 | University of Washington | Phase 2 |
| Active Not Recruiting | Intermittent Duvelisib Dosing in Treating Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymp NCT03961672 | City of Hope Medical Center | Phase 2 |
| Terminated | Study of a Triple Combination Therapy, DTRM-555, in Patients With R/R CLL or R/R Non-Hodgkin's Lymphomas NCT04305444 | Zhejiang DTRM Biopharma | Phase 2 |
| Terminated | Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial NCT03878524 | OHSU Knight Cancer Institute | Phase 1 |
| Active Not Recruiting | Modified Immune Cells (CD19/CD20 CAR-T Cells) in Treating Patients With Recurrent or Refractory B-Cell Lymphom NCT04007029 | Jonsson Comprehensive Cancer Center | Phase 1 |
| Withdrawn | Trabectedin and Venetoclax in Treating Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphom NCT03884972 | M.D. Anderson Cancer Center | Phase 1 |
| Withdrawn | Modified Immune Cells (CD19-CD22 CAR T Cells) in Treating Patients With Recurrent or Refractory CD19 Positive, NCT04029038 | M.D. Anderson Cancer Center | Phase 1 / Phase 2 |
| Active Not Recruiting | Pevonedistat and Ibrutinib in Treating Participants With Relapsed or Refractory CLL or Non-Hodgkin Lymphoma NCT03479268 | City of Hope Medical Center | Phase 1 |
| Active Not Recruiting | A Phase I/II Study to Evaluate the Safety of Cellular Immunotherapy Using Autologous T Cells Engineered to Exp NCT03277729 | Fred Hutchinson Cancer Center | Phase 1 / Phase 2 |
| Completed | Venetoclax and Ibrutinib in Patients With Relapsed/Refractory CLL or SLL NCT03045328 | Steven E. Coutre | Phase 2 |
| Completed | Metformin Hydrochloride and Ritonavir in Treating Patients With Relapsed or Refractory Multiple Myeloma or Chr NCT02948283 | City of Hope Medical Center | Phase 1 |
| Unknown | Treatment of Relapsed and/or Chemotherapy Refractory B-cell Malignancy by Tandem CAR T Cells Targeting CD19 an NCT03185494 | Chinese PLA General Hospital | Phase 1 / Phase 2 |
| Completed | Entospletinib and Obinutuzumab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia, Small Lymphocy NCT03010358 | Alexey Danilov, MD | Phase 1 / Phase 2 |
| Completed | Treatment of Relapsed and/or Chemotherapy Refractory B-cell Malignancy by Tandem CAR T Cells Targeting CD19 an NCT03097770 | Chinese PLA General Hospital | Phase 1 / Phase 2 |
| Completed | Ibrutinib in Treating Patients With Refractory or Relapsed Lymphoma After Donor Stem Cell Transplant NCT02869633 | Vanderbilt-Ingram Cancer Center | Phase 2 |
| Unknown | Anti-CD19 CAR T Infusion Combined With Allogeneic Stem Cell Transplantation for B-cell Leukemia/Lymphoma NCT03110640 | First Affiliated Hospital of Wenzhou Medical University | Phase 1 |
| Active Not Recruiting | Venetoclax and Ibrutinib in Treating Patients With Chronic or Small Lymphocytic Leukemia NCT02756897 | M.D. Anderson Cancer Center | Phase 2 |
| Terminated | Lenalidomide and Obinutuzumab in Treating Patients With Recurrent or Refractory Chronic Lymphocytic Leukemia o NCT02225275 | M.D. Anderson Cancer Center | Phase 2 |
| Terminated | Genetically Modified T-Cell Therapy in Treating Patients With Advanced ROR1+ Malignancies NCT02706392 | Fred Hutchinson Cancer Center | Phase 1 |
| Unknown | Competitive Transfer of αCD19-TCRz-CD28 and αCD19-TCRz-CD137 CAR-T Cells for B-cell Leukemia/Lymphoma NCT02685670 | The Second Affiliated Hospital of Henan University of Traditional Chinese Medicine | Phase 1 / Phase 2 |
| Terminated | Buparlisib and Ofatumumab or Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Le NCT02614508 | Emory University | Phase 1 |
| Active Not Recruiting | Bcl-2 Inhibitor GDC-0199 in Combination With Obinutuzumab and Ibrutinib in Treating Patients With Relapsed, Re NCT02427451 | Kerry Rogers | Phase 1 / Phase 2 |
| Completed | Intra-Osseous Co-Transplant of UCB and hMSC NCT02181478 | Case Comprehensive Cancer Center | EARLY_Phase 1 |
| Completed | Nivolumab and Ibrutinib in Treating Patients With Relapsed, Refractory, or High-Risk Untreated Chronic Lymphoc NCT02420912 | M.D. Anderson Cancer Center | Phase 2 |
| Completed | Selinexor and Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Aggre NCT02303392 | Jennifer Woyach | Phase 1 |
| Withdrawn | Sotrastaurin Acetate in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymp NCT02285244 | James Blachly | Phase 2 |
| Completed | Pembrolizumab Alone or With Idelalisib or Ibrutinib in Treating Patients With Relapsed or Refractory Chronic L NCT02332980 | Mayo Clinic | Phase 2 |
| Terminated | CPI-613, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non NCT02168907 | Wake Forest University Health Sciences | Phase 1 |
| Completed | Everolimus and Bendamustine Hydrochloride in Treating Patients With Relapsed or Refractory Hematologic Cancer NCT02240719 | University of California, Davis | Phase 1 |
| Terminated | Ibrutinib in Treating Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma in Patients With HIV Infection NCT02109224 | National Cancer Institute (NCI) | Phase 1 |
| Active Not Recruiting | Lenalidomide, Ibrutinib, and Rituximab in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Le NCT02160015 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Phase II MOR00208 in Combination With Lenalidomide for Patients With Relapsed or Refractory CLL, SLL or PLL or NCT02005289 | Ohio State University Comprehensive Cancer Center | Phase 2 |
| Withdrawn | Single or Double Donor Umbilical Cord Blood Transplant in Treating Patients With High-Risk Hematologic Maligna NCT01652014 | University of Medicine and Dentistry of New Jersey | Phase 2 |
| Completed | Vorinostat, Tacrolimus, and Methotrexate in Preventing GVHD After Stem Cell Transplant in Patients With Hemato NCT01789255 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Laboratory Treated T Cells in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Non- NCT01865617 | Fred Hutchinson Cancer Center | Phase 1 / Phase 2 |
| Unknown | NK Cells in Cord Blood Transplantation NCT01619761 | M.D. Anderson Cancer Center | Phase 1 |
| Completed | Lenalidomide and Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Sm NCT01886859 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Donor T Cells After Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies NCT01839916 | University of Chicago | Phase 2 |
| Unknown | Treatment of Relapsed and/or Chemotherapy Refractory B-cell Malignancy by CART19 NCT01864889 | Chinese PLA General Hospital | N/A |
| Unknown | Genetically Engineered Lymphocyte Therapy in Treating Patients With Lymphoma That is Resistant or Refractory t NCT01735604 | Chinese PLA General Hospital | Phase 1 / Phase 2 |
| Completed | Vaccine Therapy in Preventing Cytomegalovirus Infection in Patients With Hematological Malignancies Undergoing NCT01588015 | City of Hope Medical Center | Phase 1 |
| Completed | Romidepsin in Treating Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Solid Tumors With Liver Dysfun NCT01638533 | National Cancer Institute (NCI) | Phase 1 |
| Withdrawn | Mechanical Stimulation in Preventing Bone Density Loss in Patients Undergoing Donor Stem Cell Transplant NCT01558778 | Roswell Park Cancer Institute | N/A |
| Terminated | Lenalidomide With or Without Rituximab in Treating Patients With Progressive or Relapsed Chronic Lymphocytic L NCT01419795 | Fred Hutchinson Cancer Center | Phase 2 |
| Completed | Alisertib in Combination With Vorinostat in Treating Patients With Relapsed or Recurrent Hodgkin Lymphoma, B-C NCT01567709 | National Cancer Institute (NCI) | Phase 1 |
| Completed | CD19 CAR T Cells for B Cell Malignancies After Allogeneic Transplant NCT01475058 | Fred Hutchinson Cancer Center | Phase 1 / Phase 2 |
| Completed | Fludarabine Phosphate, Melphalan, and Low-Dose Total-Body Irradiation Followed by Donor Peripheral Blood Stem NCT01529827 | Roswell Park Cancer Institute | Phase 2 |
| Completed | Donor Peripheral Stem Cell Transplant in Treating Patients With Hematolymphoid Malignancies NCT01523223 | Robert Lowsky | Phase 1 |
| Completed | Ofatumumab and Dinaciclib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Small NCT01515176 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Completed | Dasatinib in Treating Patients With Chronic Lymphocytic Leukemia NCT01441882 | OHSU Knight Cancer Institute | Phase 2 |
| Terminated | Etoposide, Filgrastim, and Plerixafor in Improving Stem Cell Mobilization in Treating Patients With Non-Hodgki NCT01408043 | Case Comprehensive Cancer Center | N/A |
| Completed | Akt Inhibitor MK2206, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed Chronic Lym NCT01369849 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Completed | Veliparib, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory Lymphoma NCT01326702 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Completed | Methoxyamine and Fludarabine Phosphate in Treating Patients With Relapsed or Refractory Hematologic Malignanci NCT01658319 | Case Comprehensive Cancer Center | Phase 1 |
| Completed | Imprime PGG, Alemtuzumab, and Rituximab in Treating Patients With High Risk Chronic Lymphocytic Leukemia NCT01269385 | Mayo Clinic | Phase 1 / Phase 2 |
| Completed | MK2206 in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Leukemia NCT01231919 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Sirolimus, Cyclosporine, and Mycophenolate Mofetil in Preventing Graft-versus-Host Disease in Treating Patient NCT01251575 | Fred Hutchinson Cancer Center | Phase 2 |
| Withdrawn | Azadirachta Indica in Treating Patients With Chronic Lymphocytic Leukemia NCT01251250 | Roswell Park Cancer Institute | Phase 1 |
| Active Not Recruiting | Infection Prophylaxis and Management in Treating Cytomegalovirus (CMV) Infection in Patients With Hematologic NCT01199562 | City of Hope Medical Center | — |
| Completed | Lenalidomide After Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic Cancers NCT01254578 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Graft-Versus-Host Disease Prophylaxis in Treating Patients With Hematologic Malignancies Undergoing Unrelated NCT01231412 | Fred Hutchinson Cancer Center | Phase 3 |
| Completed | Study of Carfilzomib in Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL) or Prolymphocytic NCT01212380 | Ohio State University Comprehensive Cancer Center | Phase 1 |
| Completed | Palifermin in Preventing Chronic Graft-Versus-Host Disease in Patients Who Have Undergone Donor Stem Cell Tran NCT01233921 | Martin, Paul | N/A |
| Terminated | Deferasirox for Treating Patients Who Have Undergone Allogeneic Stem Cell Transplant and Have Iron Overload NCT01159067 | City of Hope Medical Center | Phase 2 |
| Terminated | Plerixafor and Filgrastim For Mobilization of Donor Peripheral Blood Stem Cells Before A Donor Peripheral Bloo NCT01076270 | Fred Hutchinson Cancer Center | N/A |
| Completed | AR-42 in Treating Patients With Advanced or Relapsed Multiple Myeloma, Chronic Lymphocytic Leukemia, or Lympho NCT01129193 | Amir Mortazavi | Phase 1 |
| Terminated | Alvespimycin Hydrochloride in Treating Patients With Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic NCT01126502 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Massage Therapy Given by Caregiver in Treating Quality of Life of Young Patients Undergoing Treatment for Canc NCT01053494 | Wake Forest University Health Sciences | N/A |
| Terminated | Cyclophosphamide, Alvocidib, and Rituximab in Treating Patients With High Risk B-Cell Chronic Lymphocytic Leuk NCT01076556 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Autologous Peripheral Blood Stem Cell Transplant Followed by Donor Bone Marrow Transplant in Treating Patients NCT01008462 | Fred Hutchinson Cancer Center | Phase 2 |
| Completed | CART19 to Treat B-Cell Leukemia or Lymphoma That Are Resistant or Refractory to Chemotherapy NCT01029366 | University of Pennsylvania | Phase 1 |
| Terminated | Rituximab in Preventing Acute Graft-Versus-Host Disease in a Donor Stem Cell Transplant for Hematologic Cancer NCT01044745 | University of Nebraska | Phase 2 |
| Completed | Sunitinib Malate in Treating HIV-Positive Patients With Cancer Receiving Antiretroviral Therapy NCT00890747 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Panobinostat and Everolimus in Treating Patients With Recurrent Multiple Myeloma, Non-Hodgkin Lymphoma, or Hod NCT00918333 | Mayo Clinic | Phase 1 / Phase 2 |
| Terminated | Obatoclax Mesylate, Vincristine Sulfate, Doxorubicin Hydrochloride, and Dexrazoxane Hydrochloride in Treating NCT00933985 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Rituximab in Treating Patients Undergoing Donor Peripheral Blood Stem Cell Transplant for Relapsed or Refracto NCT00867529 | Fred Hutchinson Cancer Center | Phase 2 |
| Completed | Fludarabine Phosphate, Melphalan, Total-Body Irradiation, Donor Stem Cell Transplant in Treating Patients With NCT00856388 | Roswell Park Cancer Institute | N/A |
| Withdrawn | Fludarabine Phosphate, Rituximab, and Bevacizumab in Treating Patients With B-Cell Chronic Lymphocytic Leukemi NCT00845104 | Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium | Phase 2 |
| Terminated | Bendamustine Plus Alemtuzumab for Refractory Chronic Lymphocytic Leukemia (CLL) NCT00947388 | Case Comprehensive Cancer Center | Phase 1 |
| Completed | Fludarabine Phosphate, Cyclophosphamide, Total-Body Irradiation, and Donor Bone Marrow Transplant Followed by NCT00789776 | Fred Hutchinson Cancer Center | Phase 1 / Phase 2 |
| Completed | Dasatinib in Treating Patients With Solid Tumors or Lymphomas That Are Metastatic or Cannot Be Removed By Surg NCT00608361 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Ondansetron in Preventing Nausea and Vomiting in Patients Undergoing Stem Cell Transplant NCT00795769 | Fred Hutchinson Cancer Center | Phase 2 |
| Completed | Lenalidomide and Alvocidib in Treating Patients With Relapsed or Refractory B-cell Chronic Lymphocytic Leukemi NCT00735930 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Rituximab, Cyclophosphamide, Bortezomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Lo NCT00711828 | Mayo Clinic | Phase 2 |
| Completed | Internet-Based Program With or Without Telephone-Based Problem-Solving Training in Helping Long-Term Survivors NCT00799461 | Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium | Phase 3 |
| Completed | Donor Umbilical Cord Blood Transplant in Treating Patients With Hematologic Cancer NCT00723099 | Fred Hutchinson Cancer Center | Phase 2 |
| Terminated | Obatoclax, Fludarabine, and Rituximab in Treating Patients With Previously Treated Chronic Lymphocytic Leukemi NCT00612612 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Donor Umbilical Cord Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies NCT01093586 | Case Comprehensive Cancer Center | Phase 2 |
| Completed | Sunitinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic L NCT00398112 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Genetically Engineered Lymphocytes, Cyclophosphamide, and Aldesleukin in Treating Patients With Relapsed or Re NCT00621452 | Fred Hutchinson Cancer Center | Phase 1 |
| Completed | Beclomethasone Dipropionate in Preventing Acute Graft-Versus-Host Disease in Patients Undergoing a Donor Stem NCT00489203 | Fred Hutchinson Cancer Center | Phase 2 |
| Terminated | Sunitinib in Treating Patients With Idiopathic Myelofibrosis NCT00387426 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Lower But More Frequent Dose Rituximab to Treat Chronic Lymphocytic Leukemia NCT00366418 | National Heart, Lung, and Blood Institute (NHLBI) | Phase 1 |
| Completed | High-Dose Chemotherapy With or Without Total-Body Irradiation Followed by Autologous Stem Cell Transplant in T NCT00536601 | Roswell Park Cancer Institute | N/A |
| Completed | Lithium Carbonate in Treating Patients With Acute Intestinal Graft-Versus-Host-Disease (GVHD) After Donor Stem NCT00408681 | Fred Hutchinson Cancer Center | N/A |
| Completed | AZD2171 in Treating Patients With Relapsed or Refractory B-Cell Chronic Lymphocytic Leukemia NCT00321724 | National Cancer Institute (NCI) | Phase 2 |
| Completed | A Pilot Study to Evaluate the Co-Infusion of Ex Vivo Expanded Cord Blood Cells With an Unmanipulated Cord Bloo NCT00343798 | Fred Hutchinson Cancer Center | Phase 1 |
| Terminated | SJG-136 in Treating Patients With Relapsed or Refractory Acute Leukemia, Myelodysplastic Syndromes, Blastic Ph NCT00301769 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Bevacizumab in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia NCT00290810 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Sorafenib and Bortezomib in Treating Patients With Advanced Cancer NCT00303797 | National Cancer Institute (NCI) | Phase 1 |
| Terminated | Sorafenib in Treating Patients With Relapsed Chronic Lymphocytic Leukemia NCT00303966 | National Cancer Institute (NCI) | Phase 2 |
| Terminated | Fenretinide and Rituximab in Treating Patients With B-Cell Non-Hodgkin Lymphoma NCT00288067 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Terminated | 17-N-Allylamino-17-Demethoxygeldanamycin and Bortezomib in Treating Patients With Relapsed or Refractory Hemat NCT00103272 | National Cancer Institute (NCI) | Phase 1 |
| Terminated | Flavopiridol in Treating Patients With Chronic Lymphocytic Leukemia or Prolymphocytic Leukemia NCT00098371 | National Cancer Institute (NCI) | Phase 2 |
| Terminated | 17-N-Allylamino-17-Demethoxygeldanamycin With or Without Rituximab in Treating Patients With Relapsed B-Cell C NCT00098488 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Alemtuzumab, Fludarabine Phosphate, and Total-Body Irradiation Followed by Cyclosporine and Mycophenolate Mofe NCT00118352 | Fred Hutchinson Cancer Center | Phase 2 |
| Completed | Fludarabine Phosphate, Radiation Therapy, and Rituximab in Treating Patients Who Are Undergoing Donor Stem Cel NCT00104858 | Fred Hutchinson Cancer Center | Phase 2 |
| Completed | Tacrolimus and Mycophenolate Mofetil With or Without Sirolimus in Preventing Acute Graft-Versus-Host Disease i NCT00105001 | Fred Hutchinson Cancer Center | Phase 2 |
| Terminated | Oxaliplatin, Ifosfamide and Etoposide in Treating Young Patients With Recurrent or Refractory Solid Tumors or NCT00101205 | National Cancer Institute (NCI) | Phase 1 |
| Completed | XK469R in Treating Patients With Refractory Hematologic Cancer NCT00095797 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Apolizumab in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic NCT00089154 | National Cancer Institute (NCI) | Phase 2 |
| Terminated | CCI-779 in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia NCT00086840 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Tacrolimus and Mycophenolate Mofetil in Preventing Graft-Versus-Host Disease in Patients Who Have Undergone To NCT00089011 | Fred Hutchinson Cancer Center | Phase 2 |
| Completed | CCI-779 in Treating Patients With Recurrent or Refractory B-Cell Non-Hodgkin's Lymphoma or Chronic Lymphocytic NCT00290472 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Decitabine and Valproic Acid in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia or Previo NCT00079378 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Total-Body Irradiation With or Without Fludarabine Phosphate Followed By Donor Stem Cell Transplant in Treatin NCT00075478 | Fred Hutchinson Cancer Center | Phase 3 |
| Completed | Mycophenolate Mofetil and Cyclosporine in Reducing Graft-Versus-Host Disease in Patients With Hematologic Mali NCT00078858 | Fred Hutchinson Cancer Center | Phase 1 / Phase 2 |
| Completed | Bortezomib and Fludarabine With or Without Rituximab in Treating Patients With Relapsed or Refractory Indolent NCT00068315 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Alvocidib, Fludarabine Phosphate, and Rituximab in Treating Patients With Lymphoproliferative Disorders or Man NCT00058227 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Ipilimumab After Allogeneic Stem Cell Transplant in Treating Patients With Persistent or Progressive Cancer NCT00060372 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Flavopiridol in Treating Patients With Previously Treated Chronic Lymphocytic Leukemia or Lymphocytic Lymphoma NCT00058240 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Completed | Fludarabine Phosphate and Total-Body Irradiation Before Donor Peripheral Blood Stem Cell Transplant in Treatin NCT00060424 | Fred Hutchinson Cancer Center | Phase 2 |
| Completed | FR901228 in Treating Children With Refractory or Recurrent Solid Tumors or Leukemia NCT00053963 | National Cancer Institute (NCI) | Phase 1 |
| Terminated | Thalidomide With or Without Fludarabine in Treating Patients With Hematologic Cancer NCT00009984 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Haploidentical Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic Cancer NCT00049504 | Fred Hutchinson Cancer Center | Phase 2 |
| Completed | Alemtuzumab, Fludarabine Phosphate, and Low-Dose Total Body Irradiation Before Donor Stem Cell Transplantation NCT00040846 | Fred Hutchinson Cancer Center | Phase 2 |
| Completed | Imatinib Mesylate in Treating Patients With Advanced Cancer and Liver Dysfunction NCT00025415 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Total-Body Irradiation and Fludarabine Phosphate Followed by Donor Peripheral Blood Stem Cell Transplant in Tr NCT00027820 | Fred Hutchinson Cancer Center | Phase 1 / Phase 2 |
| Completed | Monoclonal Antibody Therapy in Treating Patients With Chronic Lymphocytic Leukemia, Lymphocytic Lymphoma, Acut NCT00017472 | National Cancer Institute (NCI) | Phase 1 |
| Terminated | Arsenic Trioxide in Treating Patients With Relapsed or Refractory Lymphoma or Leukemia NCT00005786 | National Cancer Institute (NCI) | N/A |
| Completed | Fludarabine Phosphate and Total-Body Radiation Followed by Donor Peripheral Blood Stem Cell Transplant and Imm NCT00014235 | Fred Hutchinson Cancer Center | N/A |
| Completed | Thalidomide in Treating Patients With Relapsed Chronic Lymphocytic Leukemia NCT00006226 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Fludarabine Phosphate, Low-Dose Total-Body Irradiation, and Donor Stem Cell Transplant Followed by Cyclosporin NCT00006251 | Fred Hutchinson Cancer Center | Phase 1 / Phase 2 |
| Completed | Fludarabine Phosphate, Low-Dose Total Body Irradiation, and Donor Stem Cell Transplant in Treating Patients Wi NCT00005799 | Fred Hutchinson Cancer Center | N/A |
| Completed | Autologous Stem Cell Transplant Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or R NCT00005803 | Fred Hutchinson Cancer Center | Phase 1 / Phase 2 |
| Completed | Flavopiridol in Treating Patients With Chronic Lymphocytic Leukemia NCT00003620 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Bryostatin and Vincristine in B-Cell Malignancies NCT00003166 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Low-Dose Total Body Irradiation and Donor Peripheral Blood Stem Cell Transplant Followed by Donor Lymphocyte I NCT00003196 | Fred Hutchinson Cancer Center | N/A |